Home > Boards > Free Zone > Penny Fundamentals > Stock Room

$HALB Halberd Corporation Appoints New Chief Technical Officer

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
AskMuncher Member Profile
 
Followed By 378
Posts 14,361
Boards Moderated 1
Alias Born 06/07/18
160x600 placeholder
Front Month Nymex Natural Gas Fell 3.34% to Settle at $3.2400 -- Data Talk
Front Month Nymex Natural Gas for July delivery lost 11.20 cents per million British thermal units, or 3.34% to $3.2400 per million British thermal units today
Exxon on Track for Highest Close Since January 2020 -- Data Talk
VBL Shares Drop 16% After FDA Withholds Clearance for New Cancer Treatment Batches
Jounce Therapeutics Shares Rise 13% on IND Clearance for Cancer Treatment
Canada Says It's Near Plan on Easing Border Restrictions
Top Company News of the Day
STOXX Europe 600 Index Ends 0.11% Higher at 458.81 -- Data Talk
FTSE 100 Index Ends 0.36% Higher at 7172.48 -- Data Talk
DAX Ends 0.36% Higher at 15729.52 -- Data Talk
CAC-40 Index Ends 0.35% Higher at 6639.52 -- Data Talk
STOXX Europe 50 Index Ends 0.47% Higher at 3565.25 -- Data Talk
EURO STOXX 50 Index Ends 0.26% Higher at 4143.52 -- Data Talk
Helios Towers Expects to Raise $100 Million via Share Placing, Retail Offer
FTSE 100 Closes Higher Boosted by Strenghtened US Economy
JPMorgan Chase Worst Performer in DJIA So Far Today -- Data Talk
Correction to Lowe's Headline on May 19
U.S. Crude-Oil Stockpiles Likely to Fall in DOE Data, Analysts Say
Eton Pharmaceuticals Gets FDA Approval of Rezipres
Citigroup Currently Down 9 Consecutive Days, on Track for Longest Losing Streak Since December 2018 -- Data Talk
CaixaBank Partners With BlackRock on Impact Investing
UK Watchdog Puts Apple, Google Mobile Ecosystems Under Scrutiny -- Update
Bank of England's Bailey: Crypto Won't Get a 'Free Pass' on Innovation -- Financial News
Jobless Claims Seen Lower -- Data Week Ahead
U.S. Home-Builder Sentiment Declines in June Amid Rising Costs -- NAHB
USDA Announces Additional $2.6 Billion in Agricultural Aid
EU Raises EUR20 Billion in Inaugural 10-Year NextGenerationEU Bond -- Update
Luokung Technology: Defense Department Removes Chinese Military Designation
Jounce Therapeutics Gets FDA Clearance for Cancer Treatment IND
FedEx Testing Nuro Autonomous Delivery Vehicle
AskMuncher   Wednesday, 05/05/21 09:49:53 AM
Re: None
Post # of 10352 
$HALB Halberd Corporation Appoints New Chief Technical Officer to Optimize Upcoming Experiments On Radio Frequency and Laser Eradication of Disease
Press Release | 05/04/2021
JACKSON CENTER, PA / ACCESSWIRE / May 4, 2021 / Halberd Corporation (OTC PINK:HALB) announces the appointment of Dr. Mitchell S. Felder, previously a consultant to Halberd Corporation, to the position of Chief Technical Officer. Dr. Patricio Reyes, former Chief Technical Officer, has requested reduced duties due to pressing other outside commitments, but will continue to serve as a valuable contributor to the company moving forward, as a consultant.



Dr. Felder is a Board-Certified Neurologist and is the author of numerous patents, including critical patents on the development of radio frequency and laser emissive energy in the extracorporeal eradication of disease. Dr. Felder, in his new role, will oversee the coordination of testing in these fields at three university-affiliated organizations.

William A Hartman, President, CEO and Chairman stated, "This move will not only fill the spot vacated by Dr. Reyes, but is intended to maximize the benefits of our R&D tests at Youngstown State University, where we intend to conduct simultaneous experimentations on both radio frequency and laser methods to eradicate E. coli bacteria from water, as a prelude to eradicating disease from bodily fluids. Most of the required equipment and supplies have either been recently secured or are already on hand, and the start of testing is imminent. Tests on other pathogens, including Covid-19 will be conducted after demonstrating success in eliminating E. coli bacteria from distilled water, initially, and subsequently from human bodily fluids.

"Halberd's technology is protected via two existing patents on the requisite extra-corporeal (outside the body) process and eight related provisional patent applications filed in the last year.

"Our scientists believe that the advantage of radio frequency and lasers to eradicate disease antigens is that virtually no disease would be immune from these processes, and there would be virtually no known side effects from disease treatment. We are exploring both radio frequency and lasers to eradicate disease so that the most appropriate methodology can be applied to each specific disease. If successful, these processes could revolution the worldwide medical industry."

To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies:

­­­Title

Patent/ Application No.

Filing Date

Status/Document

*Method for Treating and Curing Covid-19 Infection

US 62/989981

03/16/2020

Provisional

PCT/US21/22541

03/16/2021

International PCT

*Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients

US 63/007207

04/08/2020

Provisional

Covid-19 Inflammatory Cytokine Storm Treatment

PCT/US21/26386

04/08/2021

International PCT

*Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus

US 63/013104

04/21/2020

Provisional

Treating and Curing Covid-19 Infection Utilizing a Laser

PCT/US21/28368

04/21/2021

International PCT

*Method For The Rapid Identification Of Covid-19 Infection

US 63/049441

07/08/2020

Provisional

*Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans

US 63/080735

09/20/2020

Provisional

*Nasal Spray To Prevent The Transmission Of The Covid-19 Virus

US 63/108301

10/31/202

Provisional

*Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus

US 63/111043

11/08/2020

Provisional

*Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus)

US 63/135695

01/10/2021

Provisional

Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation



View source version on accesswire.com:
https://www.accesswire.com/644260/Halberd-Corporation-Appoints-New-Chief-Technical-Officer-to-Optimize-Upcoming-Experiments-On-Radio-Frequency-and-Laser-Eradication-of-Disease


Hi my posts are for entertainment purposes only. Consult a professional. And if it lasts longer than 4 hours, call a physician with a good camera.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences